Olema Pharmaceuticals, Inc.

OLMANASDAQHealthcare● Active

$9.99

$-0.33(-3.15%)

Market Cap$872164498

P/E Ratio—

52W High$36.259

52W Low$3.89

Avg Volume1.5M

Open$10.40

Beta2.00

Overview

Olema Pharmaceuticals, Inc. (OLMA) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · OLMA · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Olema Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

OLMA insider buying and selling by quarter

OLMA insider selling · OLMA insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

7.0M3.5M0

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · OLMA ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

OLMA executive sell shares · OLMA board member insider trading · OLMA insider trading SEC filing

Showing 45 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Mar 4, 2026	Mitchell Shawnte CHIEF LEGAL OFFICER	Option	25,000	$4.37	$109K	25,000	Form 4
Mar 3, 2026	Mitchell Shawnte CHIEF LEGAL OFFICER	Option	15,000	$4.37	$66K	15,000	Form 4
Mar 4, 2026	Mitchell Shawnte CHIEF LEGAL OFFICER	Sale	24,767	$24.25	$601K	233	Form 4
Mar 3, 2026	Mitchell Shawnte CHIEF LEGAL OFFICER	Sale	15,000	$23.01	$345K	0	Form 4
Feb 2, 2026	Austin Sasha Lu VP of Finance and Controller	Award	11,700	—	—	16,188	Form 4
Jan 20, 2026	Harmon Cyrus Director	Sale	10,000	$26.88	$269K	727,770	Form 4
Jan 14, 2026	Harmon Cyrus Director	Sale	3,489	$29.12	$102K	737,770	Form 4
Jan 13, 2026	Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF.	Sale	3,822	$28.01	$107K	239,727	Form 4
Jan 15, 2026	Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF.	Sale	100,000	$28.73	$2.87M⚡	139,727	Form 4
Jan 14, 2026	Myles David C. CH. DISCOV. & NON-CLIN DEV OFF	Option	50,000	$4.87	$244K	592,761	Form 4
Jan 14, 2026	Myles David C. CH. DISCOV. & NON-CLIN DEV OFF	Sale	14,997	$28.60	$429K	577,764	Form 4
Jan 13, 2026	Myles David C. CH. DISCOV. & NON-CLIN DEV OFF	Sale	49,800	$27.60	$1.37M⚡	542,961	Form 4
Jan 14, 2026	Myles David C. CH. DISCOV. & NON-CLIN DEV OFF	Sale	35,003	$28.99	$1.01M⚡	542,761	Form 4
Jan 13, 2026	Myles David C. CH. DISCOV. & NON-CLIN DEV OFF	Sale	200	$28.49	$6K	542,761	Form 4
Jan 12, 2026	Myles David C. CH. DISCOV. & NON-CLIN DEV OFF	Sale	10,000	$28.34	$283K	144,846	Form 4
Dec 26, 2025	Bohen Sean President and CEO · Director	Gift	8,500	—	—	237,650	Form 4
Dec 22, 2025	Harmon Cyrus Director	Sale	2,881	$28.53	$82K	741,259	Form 4
Dec 19, 2025	CLARK IAN T Director	Option	12,070	$4.08	$49K	264,800	Form 4
Dec 19, 2025	CLARK IAN T Director	Option	21,520	$7.84	$169K	252,730	Form 4
Dec 19, 2025	CLARK IAN T Director	Sale	29,904	$28.83	$862K	234,896	Form 4
Dec 19, 2025	CLARK IAN T Director	Option	21,520	$3.61	$78K	231,210	Form 4
Dec 19, 2025	CLARK IAN T Director	Option	209,690	$4.41	$924K	209,690	Form 4
Dec 19, 2025	CLARK IAN T Director	Sale	193,056	$29.71	$5.74M⚡	41,840	Form 4
Dec 19, 2025	CLARK IAN T Director	Sale	41,840	$30.48	$1.28M⚡	0	Form 4
Dec 19, 2025	Myles David C. CH. DISCOV. & NON-CLIN DEV OFF	Sale	1,225	$28.08	$34K	601,656	Form 4

Mitchell Shawnte

CHIEF LEGAL OFFICER

Option

Date

Mar 4

25,000

Price

$4.37

Value

$109K

View Form 4 on SEC.gov

Mitchell Shawnte

CHIEF LEGAL OFFICER

Option

Date

Mar 3

15,000

Price

$4.37

Value

$66K

View Form 4 on SEC.gov

Mitchell Shawnte

CHIEF LEGAL OFFICER

Sale

Date

Mar 4

24,767

Price

$24.25

Value

$601K

View Form 4 on SEC.gov

Mitchell Shawnte

CHIEF LEGAL OFFICER

Sale

Date

Mar 3

15,000

Price

$23.01

Value

$345K

View Form 4 on SEC.gov

Austin Sasha Lu

VP of Finance and Controller

Award

Date

Feb 2

11,700

Price

—

Value

—

View Form 4 on SEC.gov

Harmon Cyrus

Director

Sale

Date

Jan 20

10,000

Price

$26.88

Value

$269K

View Form 4 on SEC.gov

Harmon Cyrus

Director

Sale

Date

Jan 14

3,489

Price

$29.12

Value

$102K

View Form 4 on SEC.gov

Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Sale

Date

Jan 13

3,822

Price

$28.01

Value

$107K

View Form 4 on SEC.gov

Kovacs Shane William Charles

CH. OPERATING & FINANCIAL OFF.

Sale

Date

Jan 15

100,000

Price

$28.73

Value

$2.87M ⚡

View Form 4 on SEC.gov

Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Option

Date

Jan 14

50,000

Price

$4.87

Value

$244K

View Form 4 on SEC.gov

Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Sale

Date

Jan 14

14,997

Price

$28.60

Value

$429K

View Form 4 on SEC.gov

Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Sale

Date

Jan 13

49,800

Price

$27.60

Value

$1.37M ⚡

View Form 4 on SEC.gov

Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Sale

Date

Jan 14

35,003

Price

$28.99

Value

$1.01M ⚡

View Form 4 on SEC.gov

Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Sale

Date

Jan 13

200

Price

$28.49

Value

$6K

View Form 4 on SEC.gov

Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Sale

Date

Jan 12

10,000

Price

$28.34

Value

$283K

View Form 4 on SEC.gov

Bohen Sean

President and CEO · Director

Gift

Date

Dec 26

8,500

Price

—

Value

—

View Form 4 on SEC.gov

Harmon Cyrus

Director

Sale

Date

Dec 22

2,881

Price

$28.53

Value

$82K

View Form 4 on SEC.gov

CLARK IAN T

Director

Option

Date

Dec 19

12,070

Price

$4.08

Value

$49K

View Form 4 on SEC.gov

CLARK IAN T

Director

Option

Date

Dec 19

21,520

Price

$7.84

Value

$169K

View Form 4 on SEC.gov

CLARK IAN T

Director

Sale

Date

Dec 19

29,904

Price

$28.83

Value

$862K

View Form 4 on SEC.gov

CLARK IAN T

Director

Option

Date

Dec 19

21,520

Price

$3.61

Value

$78K

View Form 4 on SEC.gov

CLARK IAN T

Director

Option

Date

Dec 19

209,690

Price

$4.41

Value

$924K

View Form 4 on SEC.gov

CLARK IAN T

Director

Sale

Date

Dec 19

193,056

Price

$29.71

Value

$5.74M ⚡

View Form 4 on SEC.gov

CLARK IAN T

Director

Sale

Date

Dec 19

41,840

Price

$30.48

Value

$1.28M ⚡

View Form 4 on SEC.gov

Myles David C.

CH. DISCOV. & NON-CLIN DEV OFF

Sale

Date

Dec 19

1,225

Price

$28.08

Value

$34K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 2

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About OLMA insider trading

OLMA insider trades

Olema Pharmaceuticals, Inc. (OLMA) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF), Zojwalla Naseem (Chief Medical Officer), Harmon Cyrus (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. OLMA insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Olema Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

OLMA insider trading · 5 questions

The insiders of Olema Pharmaceuticals, Inc. (OLMA) include executives and directors such as Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF), Zojwalla Naseem (Chief Medical Officer), Harmon Cyrus (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

OLMA board member insider tradingwho are OLMA insidersOLMA insider rosterOlema Pharmaceuticals, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026